News

Enlarge image

BusinessSweden

Sobi partners RA drug

20.02.2013 - Sobi and Savient Pharmaceuticals will co-market the Swedish company's arthritis drug Kineret (anakinra) in the U.S.

The copy of the human IL-1 receptor antagonist, which is produced in E. coli bacteria, reduces the symptoms and progression of rheumatoid arthritis (RA) by binding the access of IL-1 that causes inflammation in the joints. With the agreement Swedish Orphan Biovitrum (Sobi) hopes to expand its reach to US physicians, said Sobi COO Alan Raffensperger.

Savient's specialised sales force has strong, established relationships with rheumatologists in the US. "Kineret complements the strategic direction and focus of Savient, as we continue to build upon our existing relationships with rheumatologists and patients while marketing our own product, Krystexxa“, said Lou Ferrari, President and Chief Executive Officer of Savient.

Under the terms of the agreement, Sobi has granted to Savient the exclusive right to co-promote the sale of Kineret with Sobi in the US. Savient will market and promote Kineret beginning April 1, 2013. Sobi will remain responsible for all Kineret commercial drug manufacturing, supply, safety, and regulatory activities.

Kineret is approved as second line treatment for moderately to severely active rheumatoid arthritis (RA), in patients 18 years of age or older who have failed one or more disease modifying anti-rheumatic drugs (DMARDs).

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/sobi-partners-ra-drug.html

Clinical TrialsFrance

26.08.2016 Adocia said it would discontinue its diabetic foot ulcer programme after its lead product BioChaperone PDGF disappointed in Phase III. The French company will turn the focus on its earlier-stage products.

M&AUKSweden

24.08.2016 Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZeneca’s antibiotics for a cool US$1.5bn. With the divestment, AZ aims to further sharpen its focus.

FinancingUK

23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.

R&DDenmark

19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.

ResearchUKEU

17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).

Stock marketsGermany

15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).

LicensingDenmark

11.08.2016 Danish Genmab AS has granted Gilead Sciences license to use its DuoBody technology platform to develop bispecific antibodies for the treatment of HIV. The deal is worth up to €252m.

Clinical developmentHungaryIreland

09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.

ImmunotherapySpain

08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.

ApprovalEU

04.08.2016 After a two-year pilot period, the EMA has published its report on its adaptive pathways approach. The agency plans to “explore the concept further” and will continue to accept proposals.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NORDIC NANOVECTOR (N)34.00 NOK6.58%
  • SUMMIT (UK)4.03 GBP3.87%
  • BIOCARTIS GROUP NV (B)7.33 EUR2.66%

FLOP

  • SWEDISH ORPHAN BIOVITRUM (S)11.56 USD-7.52%
  • VITA 34 (D)4.14 EUR-7.17%
  • ADOCIA (F)53.20 EUR-5.67%

TOP

  • NORDIC NANOVECTOR (N)34.00 NOK38.8%
  • KARO BIO (S)42.00 SEK27.3%
  • MOLMED (I)0.42 EUR27.3%

FLOP

  • BIONOR PHARMA (N)0.44 NOK-22.8%
  • GW PHARMACEUTICALS (UK)514.61 GBP-13.6%
  • ZEALAND PHARMA (DK)112.00 DKK-13.5%

TOP

  • NICOX (F)10.07 EUR430.0%
  • SAREUM HOLDINGS (UK)0.74 GBP236.4%
  • GENMAB (DK)1094.00 DKK85.0%

FLOP

  • BB BIOTECH (D)44.29 EUR-83.1%
  • EVOCUTIS (UK)0.04 GBP-77.8%
  • NEUROVIVE PHARMACEUTICAL AB (S)5.65 SEK-75.4%

No liability assumed, Date: 29.08.2016